Safety and Immunogenicity of Influenza H9 Vaccine in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

353 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

H9N2 influenza circulates in animal and poultry and has caused delf limiting infections in children. Influenza H9N2 poses a pandemic threat to humans.

This study evaluates the safety and immunogenicity of adjuvanted and non-adjuvanted whole virus and virosomal H9N2 vaccines by the intramuscular route. We also assess intradermal route of administration to see if this has any advantages. The aim is to assess antibody responses before and after vaccination. The hypothesis is that lower doses of adjuvanted vaccine will induce similar antibody responses to non-adjuvanted vaccine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

NCT00992212

Pandemic Influenza Disease

COMPLETED PHASE2

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

NCT01776541

Pandemic H5N1 Influenza

COMPLETED PHASE2

H7N9 Boost in Healthy Adults

NCT02586792

Influenza

COMPLETED PHASE2

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019

Influenza

COMPLETED PHASE1

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

NCT02151344

Influenza A Virus, H7N9 Subtype

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A double-blind, single centre comparative study in which fourteen groups of 40 male and female adults \>18 years of age will be randomly allocated to receive 1.7, 5, 15 or 45 µg quantities of whole virion (WV), Aluminium -adjuvanted WV(Al-WV), and virosomal (V) influenza A/Hong Kong/1073/99 (H9N2) vaccines by intramuscular injection into the deltoid muscle; or 5 or 15microg WV vaccine administered by intradermal injection. A second dose of the same vaccine containing the same quantity of antigen as in the first dose will be administered 21 days later. Subjects will be observed for local and systemic reactions for 30 minutes after each immunisation (day 0 and 21), and will be monitored for any reactions and other adverse events for 7 days after immunisation. Blood for immunogenicity studies will be obtained at day 0 (pre-immunisation), day-21 (+4 days), and at day-42 (i.e., 21 +4 days after the second immunization). Immunogenicity will be evaluated by haemagglutination inhibition, virus neutralization,, single radial haemolysis, neuraminidase inhibition and cellular mediated responses (in a subset of 5-10 subjects from each group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine 1

influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, IM, 1.5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection

vaccine 2

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, IM, 5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection

Vaccine 3

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine vaccine, IM, 15microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection

Vaccine 4

influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, IM, 45microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection

Vaccine 5

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, alum, IM, 1.5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection

Vaccine 6

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus, alum, IM, 5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection

Vaccine 7

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 vaccine, whole virus, alum, IM, 15 microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection

Vaccine 8

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 vaccine, whole virus, alum, IM, 45microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection

Vaccine 9

influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 virosome vaccine, IM, 1.5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection

Vaccine 10

influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 virosomal vaccine, IM, 5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection

Vaccine 11

influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 virosomal vaccine, IM, 15microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection

Vaccine 12

influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection

Group Type ACTIVE_COMPARATOR

H9N2 virosomal vaccine, IM, 45microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection

Vaccine 13

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, ID, 5microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection

Vaccine 14

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection

Group Type ACTIVE_COMPARATOR

H9N2 whole virus vaccine, ID, 15microg

Intervention Type BIOLOGICAL

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H9N2 whole virus vaccine, IM, 1.5microg

influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine, IM, 5microg

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine vaccine, IM, 15microg

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine, IM, 45microg

influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine, alum, IM, 1.5microg

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus, alum, IM, 5microg

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 vaccine, whole virus, alum, IM, 15 microg

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 vaccine, whole virus, alum, IM, 45microg

influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 virosome vaccine, IM, 1.5microg

influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 virosomal vaccine, IM, 5microg

influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 virosomal vaccine, IM, 15microg

influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 virosomal vaccine, IM, 45microg

influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine, ID, 5microg

influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection

Intervention Type BIOLOGICAL

H9N2 whole virus vaccine, ID, 15microg

influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol.
* Male or female subjects over 18 years who are either healthy or have a stable medical condition.
* Able to understand and comply with all study procedures and to complete study diaries
* Individuals who can be contacted throughout the study and are available for all study visits
* Females should either be using secure contraceptive precautions including a) the oral contraceptive pill, b) condom/barrier contraception c) partner has had a vasectomy, d) be surgically sterilised, or e) post- (defined as at least two years since the last menstrual period)

Exclusion Criteria

* Any clinically significant concurrent illness or unstable medical condition including: malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or progressive renal or hepatic pathology, chronic obstructive pulmonary disease requiring oxygen therapy, and any active neurological disorder.
* Individuals with a history of anaphylaxis or serious reactions to vaccines; hypersensitivity to eggs, chicken protein, chicken feathers, influenzal viral protein, neomycin or polymixin, or products containing mercury.
* Persons with known immunosuppressive disease or who use systemic immunosuppressive drugs or other drugs listed in section 8 of the British National Formulary (BNF) or chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF to suppress a chronic disease process, or have received in the last 6 months radiotherapy or chemotherapy.
* Subjects who are at high risk of developing illnesses of the immune system.
* Individuals who are taking immunostimulant therapy or interferon
* Individuals who have received blood products or immunoglobulins parenterally during the preceding three months.
* Women should not be pregnant or lactating.
* Women who refuse to use a reliable contraceptive method throughout the study
* Known or suspected drug abuse.
* Individuals who have received another vaccine or experimental (investigational) drug in the preceding 4 weeks.
* Individuals who have previously received H9N2 vaccine
* Unable to lead an independent life either physically or mentally
* Regularly drink more than 40 units of alcohol weekly
* Individuals who have had acute respiratory pathology or infections requiring systemic antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic therapy for prevention of urinary tract infections is acceptable).
* Individuals who had a temperature over 38 degrees C in the preceding 3 days.
* Individuals who, in the opinion of the investigator, have conditions that might complicate interpretation of the study results.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes